Unicycive Therapeutics’ (UNCY) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a report published on Thursday morning,Weiss Ratings reports.

Several other brokerages also recently commented on UNCY. Benchmark raised their price target on shares of Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a report on Monday, September 15th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target (up from $9.00) on shares of Unicycive Therapeutics in a report on Wednesday. Finally, Wall Street Zen downgraded shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 25th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $4.75 on Thursday. The firm has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $5.17. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00. The company has a market cap of $83.89 million, a price-to-earnings ratio of -1.15 and a beta of 1.86.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.18. Equities research analysts expect that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC lifted its stake in Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock worth $6,537,000 after purchasing an additional 1,400,000 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics in the second quarter worth $55,000. Finally, JPMorgan Chase & Co. lifted its stake in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.